GlassScriptPhysician profile
Sergio S Sales
NPI 1427430081
$1,557.18
in general payments reported to CMS, 2019-2025
23 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $145 · 2021: $162 · 2022: $209 · 2023: $359 · 2024: $184 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $419.33 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $211.08 | 2019-2022 | |
| Lilly USA, LLC | $141.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $138.72 | 2019-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $132.02 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $94.56 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.65 | 2023-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $43.20 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $33.87 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $30.18 | 2021-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Pfizer INC. | $29.20 | 2019-2024 | |
| Exact Sciences Corporation | $29.11 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $27.43 | 2021-2022 | |
| Axsome Therapeutics, INC. | $24.89 | 2023 | Auvelity |
| Corium, LLC | $22.78 | 2023 | Azstarys |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $21.70 | 2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $18.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.64 | 2024 | Cobenfy |
| Sanofi Pasteur INC. | $16.56 | 2023 | |
| Alkermes, INC. | $15.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.30 | 2022 | |
| Genentech USA, INC. | $12.23 | 2020 | |
| Organon LLC | $8.46 | 2022-2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Sales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.